Screening

Teaches how to obtain and maintain valid informed consent through clear disclosure, comprehension checks, capacity support, voluntariness, non-coercion, and respect for refusal or withdrawal. The competency also covers consent for screening procedures, recordings, collateral contact, rescue interventions, and documentation of the consent process.

Cluster covering 31 related competencies including: Integration support, Integration therapy, Integration coaching.

Teaches protection of participant identity, sensitive clinical or occupational information, recordings, and research data. The competency covers coded identifiers, restricted access, secure handling, confidentiality safeguards, and privacy-preserving documentation.

Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.

Teaches how to detect, elicit, document, and report adverse events and serious adverse events across the participant journey. The focus is accurate source documentation, regulatory reporting discipline, follow-up, and preservation of participant safety and trial integrity.

Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.

Teaches how to assess clinical suitability before psychedelic or ketamine treatment, including medical and psychiatric screening, readiness evaluation, contraindication review, inclusion/exclusion criteria, and ongoing eligibility re-checks before dosing.

Teaches faithful delivery of manualized treatment and protocol-defined procedures while documenting and managing unavoidable deviations. The competency protects participant welfare, treatment consistency, data integrity, and sponsor oversight.

Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.

Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.

Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.

Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.

Teaches delivery of psychedelic-assisted psychotherapy according to an approved study manual across preparation, dosing, integration, and follow-up. The competency balances standardized structure with non-directive support for the participant’s therapeutic process.

Teaches accurate study documentation, source-record quality, secure data capture, Good Clinical Practice recordkeeping, IRB and sponsor documentation requirements, monitoring readiness, audit support, accountability, and retention obligations.

Teaches how to preserve blinded trial conduct across participant interactions, outcome collection, staff roles, and session procedures. The competency includes preventing accidental unblinding, minimizing bias, and using emergency unblinding only when clinically necessary.

Teaches coordinated practice across co-therapists, physicians, psychiatrists, study coordinators, principal investigators, and other care-team members. The focus is shared responsibility, clear communication, role clarity, and coordinated observation of participant status.

Teaches adherence to Good Clinical Practice, assigned study roles, protocol procedures, delegation boundaries, and applicable research regulations. The competency supports consistent execution of approved procedures across sites and participants.

Teaches how to understand ClinicalTrials.gov records and related study information, including glossary terms, registration fields, protocol descriptors, and results-reporting elements used to interpret clinical research records.

Cluster covering 2 related competencies including: Therapeutic alliance building, Therapeutic alliance and rapport building.

Teaches how to maintain clear relational and physical boundaries in emotionally vulnerable treatment settings. This includes professional conduct, rapport without overreach, explicit consent for touch, the right to revoke consent, and strict prohibition of sexual or erotic contact.

Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.

Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.

Provides supportive therapeutic presence while the patient is under the influence of ketamine. Uses calming, noncoercive guidance to help the patient navigate dissociation and emotional material.

Cluster covering 11 related competencies including: Preparation support, Psilocybin preparation, Therapeutic preparation.

Teaches structured pre-dose preparation and post-dose integration as the therapeutic frame for psychedelic-assisted psychotherapy. The therapist supports rapport, intention clarification, meaning-making, emotional processing, and consolidation of insights after dosing.

Able to practice ethically in a clinical trial environment involving a Schedule-sensitive psychoactive intervention. This includes protecting participants, adhering to protocol, and supporting valid informed participation.

Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.

Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.

Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.

Cluster covering 6 related competencies including: Therapeutic support during dosing, Nondirective dosing-session presence, Supportive dosing-session facilitation.

Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.

Cluster covering 9 related competencies including: Psilocybin facilitation, Psilocybin session support, Psilocybin facilitation basics.

Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.

The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.

Cluster covering 12 related competencies including: KAP psychotherapy delivery, Ketamine and KAP knowledge, Ketamine integration planning.

Teaches structured monitoring of depressive symptoms, response, and remission across treatment and follow-up. Learners use standardized scales and clinical review to track change and identify deterioration or non-response.

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

Clinicians and research staff must clearly educate participants about study procedures, risks, side effects, restrictions, and possible benefits, and obtain written informed consent before screening and study participation. Ethical delivery depends on transparent communication and opportunities for questions.

Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.

Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.

Teaches how to instruct participants on post-dose and study-period restrictions that reduce risk from impaired judgment, unsafe activity, prohibited substances, or behaviors that could confound study outcomes.

Teaches culturally responsive psychedelic care, including humility, anti-bias practice, Indigenous and traditional-use awareness, cultural appropriation concerns, diversity and inclusion, and respectful work with marginalized communities.

Teaches clinicians and research staff to understand the purpose, limits, scoring, interpretation, and clinical meaning of psychological measures and study instruments used to evaluate symptoms, functioning, safety, and treatment outcomes.

Understand the pharmacology and interaction risks of 5-MeO-DMT/BPL-003, including serotonergic and cardiovascular concerns. This knowledge informs safe preparation, exclusion screening, and monitoring.

The study used standardized anxiety measures and followed patients for 2 months and 12 months, implying competence in tracking outcomes over time. Therapists should be able to assess symptom change and sustained benefit using structured follow-up.

Maintain a contained therapeutic environment that protects the patient’s privacy and minimizes unwanted exposure. The session structure emphasizes confidentiality and controlled access to stimulation and outside contact.

Teaches structured clinical interviewing and assessment administration for PTSD and related symptom domains, including symptom severity, functional impairment, risk factors, and appropriate use of standardized assessment tools.

Support decision-making about ongoing treatment after trial completion, particularly for participants who received escitalopram. The clinician helps participants consider whether to continue, taper, or return to usual care.

Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.

Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.

Cluster covering 4 related competencies including: Psychedelic therapy workflow, Psilocybin psychotherapy framework, Psilocybin-assisted psychotherapy framework.

Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.

Ability to administer and interpret structured interviews, clinician ratings, and self-report measures used in the study. Therapists contribute to eligibility, safety, and outcome assessment.

Therapists and study clinicians perform detailed biopsychosocial interviewing during preparation and screening. This supports treatment planning, risk assessment, and therapeutic understanding.

Facilitators must be able to contain and support intense psychological distress during the session. The study notes that the experience could be emotionally difficult even when participants felt safe.

Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.

Prepare participants for the dosing session and guide them through standardized procedures. The facilitator should ensure readiness, adherence to study rules, and smooth progression through the session schedule.

Therapists/facilitators must know the psychiatric and medical conditions that make KPT unsafe or inappropriate. Safe practice depends on excluding high-risk individuals.

Knows when to involve physicians, psychologists, and independent safety oversight. Complex psychedelic sessions require clear escalation pathways and team coordination.

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

Cluster covering 2 related competencies including: Preparation of set and setting, Client preparation and therapeutic set/setting.

The training includes appropriate use of therapeutic touch as part of safe delivery. Learners are expected to use touch judiciously and within ethical boundaries.

The framework implies competence in evaluating both symptom change and subjective outcomes over time. The study used standardized anxiety measures and qualitative interviews to assess sustained effects and patient-reported change.

Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.

Therapists should accurately represent the current evidence base and avoid overstating efficacy or durability. The article notes significant short-term benefit but also the need for larger multicenter trials and longer follow-up.

Understand the characteristic acute experiential domains elicited by ayahuasca. This includes perceptual, somatic, cognitive, affective, mystical, and temporal-spatial alterations.

Administer and interpret psychological and psychometric measures relevant to mood, cravings, expectations, mystical experience, ego dissolution, and functioning. Facilitators must accurately support questionnaire-based assessment across time points.

Therapists and facilitators should communicate treatment effects responsibly and acknowledge methodological limitations. The paper notes small sample size, lack of long-term control group, and need for further study of mechanisms.

Provide a calm and supportive environment during treatment to reduce distress and support tolerance of the experience. The case report notes food, rest, and a quiet place as part of care.

Ability to evaluate alcohol and other substance use patterns using standardized tools and clinical interview. This is essential for eligibility, safety, and outcome monitoring.

Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.

Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.

The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.

The therapist is responsible for giving truthful, individualized preparation and reassurance about the experience, including likely sensations, risks of resistance, and expectations for conduct. The preparation aims to reduce fear, improve cooperation, and support voluntary participation.

Cluster covering 4 related competencies including: Integration and debriefing, Integration and debriefing facilitation, Integration and post-session debriefing.

Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.

Uses motivational interviewing methods to strengthen intrinsic motivation and commitment to change. Tailors discussions to the participant’s ambivalence, goals, and readiness to change drinking behavior.

Conduct preparatory sessions that orient the subject, assess readiness, and set expectations for MDMA-assisted psychotherapy. These sessions are used to prepare for safety, adherence, and therapeutic engagement.

Participant safety and wellbeing must take precedence over scientific objectives at all times. Therapists must communicate and operationalize this priority throughout screening, treatment, and follow-up.

Therapists may record sessions only with explicit participant consent and must handle recordings for training and research within protocol limits. Recording is part of the therapeutic and scientific framework, not routine clinical use.

Administer study measures and structured assessments on schedule, including psychological, spiritual, and neurobehavioral instruments. This includes both paper-based and Storyline-based assessments.

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

Therapists are expected to provide consistent empathic presence, nonjudgmental attunement, and deep listening throughout the process. This includes validating feelings, listening for deeper meaning, and creating psychological permission for openness.

Therapists/facilitators should be able to judge whether therapeutic change reaches clinically meaningful thresholds, not just whether symptoms improve numerically. This supports informed ongoing care and communication about benefits and limitations.

The facilitator must administer and coordinate patient-rated and clinician-rated measures while minimizing bias. Assessments should be completed independently and in the correct order.

Cluster covering 5 related competencies including: Cardiac safety monitoring, Ketamine infusion monitoring, Ketamine infusion administration.

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

Therapists must be able to elicit a full account of the dosing experience without overinterpreting it. The goal is to help participants remember, narrate, and reflect on their experience in detail.

Facilitators are responsible for ensuring that participants have provided informed consent before receiving MDMA-assisted therapy. This reflects an ethical and regulatory duty central to work with investigational treatments.

Understand the clinical and neurobehavioral rationale for PE and exposure-based treatment. The therapist should know how extinction learning is conceptualized in the study model.

Therapists must protect voluntariness when potential participants are also their patients. Independent evaluation should be used to reduce pressure or perceived coercion in recruitment and consent.

Study clinicians are responsible for administering study drug, ensuring correct dose assignment, and supervising safe oral ingestion during blinded sessions. This includes verifying visit-specific randomization information and ensuring dosing is delivered under the blinded workflow.

Therapists must meet licensure requirements and work within supervision structures appropriate to their training and role. Unlicensed or PAP-inexperienced staff require direct supervision.

The manual specifies baseline professional requirements for study therapists. These include licensure and substantial clinical experience with psychiatric populations.

Coordinate effectively with the study clinician, medical monitor, rater team, and MRI staff. Facilitation is embedded in a broader clinical-research workflow requiring timely communication.

Understands and applies the protocol-defined criteria for treatment-resistant major depressive disorder, including diagnostic confirmation, episode severity, and prior treatment failure requirements. Must verify both current and historical antidepressant nonresponse and ensure the participant remains eligible at baseline.

Know the sequence, timing, and purpose of screening, preparation, dosing, scanning, follow-up, and unblinding visits. The therapist/facilitator must be able to work within the full protocol structure.

Capacity to conduct assessments and therapy sessions virtually when needed while preserving safety and confidentiality. The study permits telehealth sessions for certain visits and contingencies.

Teaches clinicians to recognise their role boundaries, align services with training, licensure, supervision, and organisational policy, and refer or escalate when participant needs fall outside their scope of competence.

The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.

Facilitator must understand opioid use disorder, medication-assisted treatment, and the clinical rationale for adjunctive psychotherapy. The protocol frames MORE+KAP as an investigational augmentation to buprenorphine treatment.

Engages in ongoing supervision and accepts feedback to maintain treatment quality. Supports corrective action when performance is unsatisfactory.

The intervention involved two separate psilocybin dosing sessions 3 weeks apart under a randomized controlled protocol, implying the need for facilitators to reliably support treatment according to a fixed schedule and study procedures.

Competence in delivering online psychotherapy through secure platforms consistent with privacy requirements. The protocol specifies secure videoconferencing in compliance with HIPAA guidelines.

Document participant experiences and relevant observations to support continuity, recall, and study integrity. Notes may also serve as a participant memory aid after dosing sessions.

After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.

Reviews laboratory and ECG data for clinically relevant abnormalities and determines whether continued participation is appropriate. Escalates abnormalities requiring repeat testing or specialist input.

The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

The facilitator must ensure non-responders are transitioned safely back to clinical care. Continuity of care is explicitly required to support ongoing psychiatric treatment.

Teaches clear communication of behavioral requirements before dosing sessions so conditions are standardized and preventable risks are reduced. Staff confirm that participants understand and follow pre-session instructions.

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

Follows the study's operational rules for dose timing, progression, and stopping conditions. Reliable execution is necessary for both safety and interpretability of results.

Facilitators must know the risks and contraindications associated with ayahuasca use. They should identify medical and psychological factors that make participation unsafe or require extra caution.

Facilitators must competently administer and interpret clinician-rated ADHD and global severity measures. Accurate scoring is essential because these scales determine eligibility and outcomes.

Although formal measurements may be conducted by another researcher, therapists/facilitators must work within a protocol that includes repeated anxiety assessments and daily diaries of anxiety, pain, and medication use. This implies competence in reinforcing adherence to monitoring procedures and integrating findings into care awareness.

Therapists should orient to and explore the participant’s somatic experience, both in experimental and integrative sessions, as a central channel of processing.

Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.

Have a working understanding of moderate to severe AUD, relapse processes, craving, withdrawal, and common comorbidities. This knowledge is required to deliver the integrated treatment model safely and effectively.

Therapists should understand the participant’s support network and appropriately involve support persons when relevant and desired.

Uses assessment findings to individualize therapy and medication-session preparation. Adapts the approach based on participant response, goals, and clinical presentation.

Collect smoking-related behavioral data and participant-reported outcomes repeatedly across the trial. Facilitators must accurately gather self-report, breath CO, urine, and questionnaire data according to protocol.

Teaches the use of independent or blinded assessors to reduce expectancy and observer bias, preserve separation between therapeutic and rating roles, manage unblinding risks, and protect outcome validity in open-label or partially blinded designs.

Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

Therapists must practice within the population and setting defined by the manual, limiting use to approved clinical trial subjects with PTSD. This boundary helps protect participants and preserves research integrity.

Ability to monitor for short-term cognitive impairment following psychedelic administration. The study included tests designed to detect decrements in attention and processing speed.

Therapists function within a medically supervised ketamine model and must coordinate closely with clinicians responsible for dosing oversight and safety clearance. This includes understanding role boundaries and supporting monitoring workflows.

Can safely administer vaporized GH001 using standardized equipment and procedure. Accurate delivery and participant instruction are essential to reliable dosing.

Therapists must coordinate with prescribing clinicians and existing psychotherapists when relevant, while respecting consent and confidentiality. Communication should support safety, continuity, and protocol integrity.

Work within an approved research framework that has institutional review board authorization. Ethical practice requires adherence to the approved study protocol and oversight requirements.

Facilitators need to understand the full treatment sequence and how each phase contributes to safety and treatment delivery. The intervention depends on correct sequencing and timing.

Safety monitoring in this context includes tracking not only adverse psychiatric states but also broader psychological, emotional, existential, and spiritual outcomes. Clinicians should watch for changes across multiple domains that may affect patient functioning and care needs.

Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.

The facilitator must minimize bias in how assessments are administered and in how participant responses are handled. This is important because the trial is open-label and relies heavily on patient-reported outcomes.

Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.

The protocol explicitly addresses the risk of undue influence when investigators recruit current or former patients, requiring safeguards and ongoing monitoring for coercion.

Ability to manage the study schedule, windows, and follow-up procedures accurately. This supports treatment delivery and valid outcome collection.

Ability to administer standardized clinical ratings consistently and under supervision. Reliable measurement is essential for efficacy and safety endpoints.

Distinguish psychotherapy/facilitation functions from outcome assessment and other research tasks. Separation reduces bias and protects the integrity of blinded assessments.

Ability to monitor for opioid use recurrence, other substance use, and ketamine misuse during the trial. The clinician must recognize relapse risk and take action when substance use worsens.

Therapists/facilitators require knowledge of treating patients with moderate-to-severe major depressive disorder in the context of psychedelic-assisted therapy. The target population in the trial establishes disorder-specific clinical knowledge needs.

Because the protocol involved specific LSD doses, active placebo control, and session spacing, facilitators need applied skill in implementing dosing-session procedures safely and consistently. This includes maintaining therapeutic support while adhering to protocol constraints.

Teaches the requirement for site personnel to be trained and certified on protocol-specific assessments, psychiatric instruments, rating scales, and study procedures before performing them in the trial.

Facilitators need conceptual knowledge of normal grief, prolonged grief disorder, and the rationale for preventive and therapeutic grief care. This informs formulation, pacing, and risk awareness in the protocol.

The handbook explicitly states that the experience should be fully explained and that the subject should accept it voluntarily. Coercion is framed as both unethical and therapeutically counterproductive.

The protocol expects involvement of relatives in follow-up, indicating a facilitator competency in engaging collateral supports. This helps verify outcomes and sustain recovery monitoring.

Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.

Cluster covering 2 related competencies including: Trauma-informed care, Trauma-informed psychedelic care.

Teaches practitioners to read and understand clinical protocols, treatment manuals, and evidence-based psychedelic care procedures. The focus is knowing how protocol requirements shape preparation, dosing, integration, documentation, and safety responsibilities.

Teaches practitioners to identify and apply relevant legal, regulatory, ethical, and institutional requirements, including documentation, consent, reporting, controlled-substance, and jurisdiction-specific obligations.

The course explicitly discusses confidentiality, especially in underground practice and with anonymous practitioners. Learners are expected to understand confidentiality as a core part of maintaining safe and effective psychedelic care relationships.

Responds to distressing anxious or psychotic reactions with verbal de-escalation and, if needed, rescue medications. Escalates intervention in a stepwise manner based on clinical response.

Develop follow-up care after the acute ibogaine period to support behavior change and relapse prevention. The manual emphasizes that the treatment session alone is not enough for long-term recovery.

Lead facilitators were doctoral-level psychologists or physicians with major depressive disorder treatment experience, and co-facilitators had at least a bachelor’s degree in a mental health-related field. The source therefore indicates role-appropriate clinical background and experience requirements.

The intervention targets anxiety associated with life-threatening diseases, so therapists need knowledge of the psychological burden of severe medical illness and the clinical presentation of anxiety in this population. They must be able to formulate treatment needs in medically ill patients.

Therapists must remain with participants at the end of and immediately after experimental sessions until emotional stability is established. This requires real-time clinical judgment about readiness for reduced supervision.

The therapist must exercise clinical judgment about who may benefit, who may have difficulty surrendering defenses, and where evidence is limited. The handbook emphasizes uncertainty, need for research, and cautious selection based on insecurity, rigidity, suspicion, diagnosis, and treatment goals.

Ability to contribute to evaluation of the effectiveness of LSD-assisted psychotherapy. The study is explicitly described as investigating safety and effectiveness.

Track onset, duration, and phases of ibogaine effects as part of clinical monitoring. The manual describes multiple stages of effect and expects the provider to observe them carefully.

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

Collect and interpret baseline behavioral, psychiatric, and medical history relevant to psilocybin research. This information is used to determine eligibility and contextualize outcomes.

Therapists must help participants manage disclosure, social support, and media contact carefully to protect privacy and emotional safety. They should advise discretion without controlling the participant's choices.

Work within protocol-defined limits of therapist support. The trial excluded participants whose conditions could jeopardize rapport given those limits, underscoring the need for clear boundaries.

Knows the conditions that may disqualify a person from ketamine treatment and can apply that knowledge during screening. Recognizes medical, psychiatric, pregnancy-related, and substance-related contraindications.

Ability to attend closely to participant responses during altered states and validate them without pathologizing normal psychedelic phenomena. This supports safety and meaning-making.

Understand that classic psychedelics can cause moderate increases in blood pressure, heart rate, temperature, and pupil size without necessarily indicating severe toxicity. Proper interpretation helps avoid overreaction while remaining vigilant.

Safe delivery requires coordination among therapists, physicians, nurses, blinded assessors, outside therapists, and emergency services.

Review laboratory and biomarker data for clinically significant abnormalities, including chemistry, hematology, coagulation, and alcohol biomarkers. This supports medical safety surveillance during follow-up.

Because interviews and questionnaires may provoke emotional reactions or fatigue, facilitators must respond supportively and mitigate burden. This includes addressing distress during assessments and offering breaks.

Recognizes medical factors that may increase risk during inhaled 5-MeO-DMT administration. Medical clearance is required before dosing.

Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.

Understands the optional nature and operational limits of biomarker and pharmacogenomic collection. Ensures consent, timing, fasting guidance, and sample handling requirements are respected.

Knowledge of the trial’s primary, secondary, and exploratory endpoints and the instruments used to assess them. This enables accurate administration and interpretation of study procedures.

Facilitators are expected to monitor for signs of misuse, diversion, dependence, or other abuse-related phenomena even though the medication is administered only on-site. They must also recognize protocol violations or dropout patterns that may signal abuse liability concerns.

Ability to assess whether the target acute psychedelic experience has occurred using the study-defined scale and threshold. This was used to guide individualized dosing.

Conduct or support psychiatric screening using clinical interviews and structured diagnostic tools. The goal is to establish baseline mental health status and detect exclusionary disorders or instability.

Identify and document possible post-dose reactivation or flashback-like experiences. The therapist must capture timing, context, emotional valence, and functional impact of these events.

Facilitators need knowledge of conditions and medications that may make 5-MeO-DMT unsafe or inappropriate. They should identify possible interactions and discuss them clearly before participation.

Facilitators should understand that treatment aims include symptom reduction and improved functioning. Support work should attend to both emotional processing and real-world disability.

Facilitators should refer participants to qualified professionals when their needs exceed available support. This is part of responsible care and boundary awareness.

Coordinate multi-visit assessment timelines around the psilocybin session. Follow-up data collection is essential for longitudinal outcomes and requires careful scheduling.

Facilitators must watch for slowed breathing, sleep apnea-related hypoxia, disordered breathing, and oxygen desaturation. Oxygenation needs ongoing assessment during the acute and post-acute periods.

Given the risk of high attrition, facilitators need strong engagement and follow-up skills. The protocol explicitly notes the importance of respecting time commitments, tracking procedures, and strong interpersonal skills of study personnel.

Carry out baseline medical safety checks prior to intervention initiation. These assessments reduce risk and support participant suitability.

Collaborates with patients, medical practitioners, and referring providers to support individualized care. Helps patients consider alternatives and coordinate ongoing treatment needs.

Therapists must assess the participant’s social support network and help plan appropriate use of supportive relationships during treatment. They should guide participants about the potential benefits and risks of sharing their experiences with others.

Use Subjective Units of Distress Scale ratings to track fear activation and extinction during PE sessions. This requires eliciting reliable distress ratings and using them to guide exposure processing.

Because cognitive performance during treatment is a named secondary outcome, clinicians involved in care should be able to monitor and document cognitive functioning relevant to treatment participation. This supports safety oversight and interpretation of treatment effects.

The therapist should assess both the immediate experience and longer-term change, using structured observation, self-report, and reports from others where possible. The handbook treats evaluation as difficult but necessary for understanding therapeutic effects.

Therapists/facilitators should know the main assessment domains used in KPT research and clinical monitoring, including craving, depression, anxiety, anhedonia, addiction severity, and purpose in life. This knowledge supports case formulation and tracking change.

The therapist/facilitator or designated rater must administer and interpret multiple structured clinical scales reliably. Training and separation of roles are required to preserve rating quality and blinding.

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.

Teaches how to interpret the psychedelic clinical evidence base, compare strength of evidence across indications, understand mechanism theories, and critically appraise research claims. The competency supports evidence-informed practice rather than relying on general field narratives.

Ability to apply KAP flexibly across multiple diagnostic presentations. The article describes benefit in patients with a wide variety of diagnoses.

Ensure required abstinence conditions are met before dosing and make clinical judgments about rescheduling or exclusion when they are not. This protects safety and protocol integrity.

Understands diagnostic and clinical features of alcohol dependence and related severity measures used in the protocol. Uses this knowledge to inform eligibility, treatment focus, and outcome interpretation.

Clinicians must recognize the life-threatening nature of alcohol withdrawal and ensure adequate detoxification before treatment. Postponement and medical supervision are required when withdrawal risk is present.

Detect and address strains in the therapeutic relationship over the course of treatment. The discussion recommends frequent assessment and repair of alliance ruptures.

Competent delivery includes monitoring psychosocial functioning in addition to depressive symptoms. The source reports psychosocial functioning as a treatment outcome sustained through follow-up.

Administer study assessments in the correct order and in the correct format. The protocol depends on reliable, standardized administration by trained site personnel and central raters.

Demonstrate standardized rating competence and maintain reliable measurement over time. The protocol emphasizes training, calibration, and ongoing checks to prevent drift.

Administer and interpret the study's psychosocial measures relevant to existential distress, depression, spiritual well-being, and death-related distress. These assessments are used for screening and outcome monitoring.

Before administration, facilitators should assess readiness and factors that could increase the chance of a difficult session. The source highlights that preoccupation, rigidity, low trust, and poor support can worsen experiences.

Understand how therapeutic alliance is measured and interpreted in psychedelic-assisted therapy research. The study used the WAI-SR with goal, task, and bond subscales.

Therapists and study staff must manage participant distress and fatigue associated with questionnaires and interviews. Competence includes pacing, offering breaks, and responding supportively to emotionally evocative content.

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

Therapists and research facilitators should evaluate how participants experienced study involvement, including perceived costs, benefits, and pressure to participate. This reflects an ethical responsibility to monitor the quality and voluntariness of participation over time.

The therapist/facilitator must understand potential drug-interaction concerns and formulation-related differences that could alter tolerability or safety. The source mentions caution with antiemetics and alternative preparations.

Trained staff must administer and/or supervise a battery of behavioral tasks and self-report instruments consistently across baseline and drug sessions. Some measures are verbally administered by clinicians or coordinators and require standardized delivery.

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

Evaluate whether a person is an appropriate candidate for ibogaine treatment by balancing potential benefit against medical risk. This includes identifying treatment-refractory opioid use disorder and weighing cardiotoxicity and other safety concerns against the harms of untreated substance use disorder.

Performs repeated blood pressure screening and interprets values against protocol thresholds before allowing dosing. This includes recognizing measurement artifact and repeating readings when needed.

Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

Assess whether an event is related to treatment and resolve uncertainty through team discussion and regulatory escalation. The protocol uses a structured causality framework from unrelated to definitely related.

Can determine which aspects of the treatment setting are experienced as meaningful by clients. This supports tailoring facilitation and understanding what contributes to engagement and change.

Some listed programs explicitly teach clinical documentation and related practice management skills. This suggests learners may be expected to document care, coordinate treatment processes, and work within structured clinical workflows.

Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.

Understand the transition from blinded randomized treatment to open-label MDMA-assisted therapy for eligible participants. This includes separate consent, revised scheduling, and altered assessment timing.

After completion of PE, patients are assessed over a 3-month follow-up period at multiple time points, requiring clinician or facilitator competence in longitudinal follow-up procedures. This includes maintaining contact and collecting outcome information consistently.

Collects and records substance use, withdrawal, and follow-up data accurately and responsibly in clinical or research settings.

Clinicians should be able to evaluate and support treatment acceptability from both participant and clinician perspectives. The pilot reported high acceptability ratings by participants and study clinicians.

Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.

Knowledge of anorexia nervosa symptomatology, risk, and clinical instability relevant to screening and treatment monitoring. The study requires awareness of eating-disorder-specific risks and outcomes.

Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.

Document eligibility decisions, registrations, and protocol compliance accurately and completely. This includes signed checklists, source documentation, and investigator attestation.

Manage optional future-contact procedures ethically and separately from current study participation. Participants may choose whether to authorize future contact without affecting present enrollment decisions.

Prevent dehydration during and after ibogaine treatment. The manual stresses that patients may not feel like drinking and that dehydration can become dangerous, especially if vomiting occurs.

Understands the implications of PET, MRI, blood sampling, and TMS-EEG procedures for participant comfort and safety. While not necessarily performing these procedures, the therapist/facilitator should know their risks and scheduling constraints.

Therapist/facilitator practice in the study must align with equity, diversity, and inclusion commitments by avoiding exclusions based on protected or social identity characteristics outside protocol-defined scientific/safety criteria. This supports ethically sound participant engagement.

Understand that changes in cerebral blood flow were observed after ayahuasca intake in regions implicated in mood and emotion regulation. Facilitators should be able to contextualize these findings without overinterpreting them clinically.

Determine whether a patient is intoxicated enough to impair participation in preparation sessions. This requires clinical judgment focused on comprehension and therapeutic alliance.

Collect biological samples and interpret their role in safety and exploratory analyses. Facilitators need procedural competence in sample handling and visit timing.

The facilitator must make repeated documented efforts to contact participants who miss visits. Follow-up processes differ for responders and non-responders.

5-MeO-DMT produces a very short but intense experience, which changes facilitation demands. Facilitators must be prepared for rapid transitions into and out of the altered state.

Identify concurrent medications or recent drug exposures that may interact dangerously with ibogaine. The clinician/facilitator must understand that ibogaine can potentiate other drugs and that certain psychiatric medications or toxic agents may contraindicate treatment.

Screen for co-medications that may prolong QTc or affect CYP2D6 metabolism. This is critical to reduce confounding and prevent additive toxicity.

Therapists must understand clinically significant drug interactions with ibogaine, including QT-prolonging, serotonergic, centrally acting, and CYP2D6-related medications. This knowledge informs screening, tapering, and dosing decisions.

Use video-based direct observation methods to verify medication intake and prevent dose stacking. This is a core adherence-monitoring function in the protocol.

Uses an open, collaborative MI style to engage participants and support change. Employs reflective listening, eliciting change talk, and reinforcing motivation without confrontation.

Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

Sequences study procedures correctly to reduce bias and protect participant safety. Particularly prioritizes PROs, clinician ratings, and dosing-day procedures in the required order.

Understands the clinical profile of opioid use disorder and identifies individuals with opioid dependence who may be considered for ibogaine-based detoxification in observational or treatment settings.

Clinicians must identify appropriate participants and recognize that the study enrolled psychiatrically healthy nicotine-dependent smokers. Competence includes screening for psychiatric suitability and tobacco dependence characteristics relevant to treatment eligibility.

Supports structured administration and observation within a clinical trial or supervised research setting. Uses protocol-based timing, assessments, and follow-up consistent with phase I human studies.

The therapist/facilitator must ensure medical suitability before ayahuasca administration by checking for conditions that increase risk. Screening should include physical exam, laboratory testing, and pregnancy assessment when indicated.

Adheres to organizational code of ethics, privacy policy, electronic communication policy, and applicable laws. Maintains professional conduct across contractor and clinic arrangements.

Conducts a retrospective psychiatric interview to judge minimal clinical improvement on the current antidepressant regimen. Uses multiple information sources and clinical observation to determine whether the participant meets screening requirements.

Coordinate with remote central raters for standardized outcome assessment while preserving privacy and safety. The site must ensure the setting is private and that safety concerns are relayed back to the site promptly.

Recognizes that a study involving a psychoactive compound requires careful attention to participant safety during screening and participation. Even though the source does not detail procedures, a facilitator must anticipate risk-aware monitoring and escalation.

Clinicians must ensure participants meet day-of-session safety requirements before psilocybin is administered. This includes verifying toxicology, pregnancy, alcohol abstinence, and adherence to protocol restrictions.

Understands the screening instruments and the respective roles of site staff and independent raters. The facilitator must collaborate with rater findings while maintaining appropriate boundaries and blinding.

Supports rigorous conduct of randomized controlled safety studies by maintaining protocol adherence and minimizing bias. Protects the validity of safety, tolerability, and exploratory efficacy assessments.

Confirm ongoing eligibility throughout the study and recognize conditions that require withdrawal or reassessment. Eligibility is not static and must be checked before key sessions.

Organizers must decide whether to accept or refuse participants based on screening and interview data. When in doubt, the guidance favors non-acceptance.

Prepare participants to complete emotional processing tasks and questionnaires accurately. Staff must teach task procedures and ensure participants understand expectations before scanning and follow-up assessments.

Ability to conduct initial phone-based screening to determine whether a potential participant appears eligible for the protocol. This requires efficient, accurate triage before in-person assessment.

Monitor body temperature during sessions and intervene if it rises beyond expected limits. The protocol specifies active cooling steps and escalation thresholds.

Conducts evaluations and psychotherapy with sensitivity to distress, moral injury, grief, and burnout. The therapist must avoid unnecessary burden while still collecting required data.

Facilitators require knowledge of the therapeutic context, including that psilocybin is being investigated as a rapid-acting treatment for major depressive disorder. This includes understanding the expected timeframe of symptom assessment and response.

The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.

Facilitators must know the study timeline to conduct therapy and safety checks at the correct times. They should understand which visits are in person, virtual, or questionnaire-only and what assessments occur at each stage.

Understand the domains assessed in the Storyline psychiatric and neurological interviews and use this knowledge to support accurate administration and interpretation of study tasks. Domains include cognition, mood, homeostasis, social support, and psychosis/suicidality screening.

The protocol depends on video/audio recordings for later transcription, qualitative coding, and adherence review. Staff must understand how these recordings support both science and supervision.

The study relied on self-reported symptomatology, so clinicians should understand how to gather and interpret patient-reported outcomes relevant to psychiatric and existential distress. This includes using subjective reports as meaningful indicators while recognizing their limits.

Teaches applied competence through role play, case discussion, peer consultation, seminars, mentorship, and learning-community structures. The emphasis is translating theory into practice, receiving feedback, and developing reflective clinical judgment with peers.

Cluster covering 7 related competencies including: Psychedelic therapy foundation, Psychedelic therapy foundations, Psychedelic practice fundamentals.

Cluster covering 4 related competencies including: Ethical practice, Ethics in psychedelic care, Ethics and ethical practice.

Teaches work with clinically complex contexts such as trauma, palliative care, and other nuanced presentations where ethical judgment, scope discipline, careful assessment, and individualized support are required.

Teaches how participants move through lawful access routes and coordinated care pathways. The competency covers referral navigation, team handoffs, and the practical steps needed to connect eligible participants with appropriate treatment or study settings.

Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.

The curriculum includes practical assessment work and use of intake templates and assessment forms. Students learn to evaluate client fit and tailor support based on client goals and needs.

The page highlights best-in-class clinical training for drug trials and AI-supported evaluation. Learners are expected to refine skills quickly and receive targeted feedback in training or evaluation contexts.

Learners are taught how to work with clients who already have an outside therapist and to coordinate closely with existing treatment. The course also mentions treatment flow for groups and couples.

The program emphasizes that it prepares people for therapeutic and facilitative roles within a collaborative care framework, not independent medical practice. Learners are expected to understand role boundaries, especially around prescribing and administration.

The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.

The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.

The page repeatedly points learners to manuals, checklists, PDFs, and reference materials, indicating a practical emphasis on coordination and structured preparation. This suggests learners should be able to organize session materials and support process consistency.

The practicum includes retreat team debriefs, supervisor meetings, and assessment presentations. This signals an expectation that learners can reflect on practice, receive feedback, and integrate learning.

Teaches providers to recognise access barriers and health disparities, adapt services for diverse participant needs, and deliver care in ways that are inclusive, accessible, culturally responsive, and practically reachable.

Trainees receive templates such as consent and intake forms, informational documents, and guidelines, which implies competence in using standardized practice materials. The page also signals procedural support for safe and organized care delivery.

The course explicitly states that facilitators are guided in safety, ethics, and responsibility. Learners are expected to recognize and manage the unique risks of working with altered states.

The course teaches the overall PAP workflow from screening through follow-up. Learners are expected to understand and explain each phase of treatment in a structured way.

Students complete 50 supervised practicum hours and receive expert feedback while working with real clients. This is intended to translate theory into competent applied practice.

The program states it prepares facilitators to address the needs of clients, patients, or community members from diverse faith traditions and communities of origin. Learners are expected to adapt facilitation to varied settings and worldviews.

The practicum requires placements at pre-approved sites and emphasizes legal and ethical standards. Learners are exposed to different settings, including clinical, retreat, and harm reduction organizations.

The page explicitly signals the value of bilingual and bicultural heritage as a foundation for practice. This points to competence in communicating and relating across language and cultural context.

The page highlights extensive patient care experience and a background in holistic counseling psychology, suggesting practical competence in supporting participants in clinical or care environments. This is more general care-setting competence than protocol-specific technique.

Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.